Treatment of recurrent malignant supratentorial gliomas with carboplatin (CBDCA).
Twenty patients with malignant supratentorial gliomas progressing after radiation therapy and chemotherapy with nitrosoureas received intravenous carboplatin, 450 mg/m2. Courses of therapy were repeated every four weeks. Therapeutic evaluation was performed monthly using neurologic examination and CT scan of the brain. Of 19 patients evaluable for response, 2 (10%) responded to therapy and 6 (30%) had stable disease. The estimated median time to tumor progression for responding and stable patients was 6 months. Median duration of survival was 6 months for all patients. Of 20 patients evaluable for toxicity, none had renal or auditory toxicity. Side effects consisted of hematologic toxicity in 4 patients (20%): one patient had grade 4 toxicity requiring discontinuation of carboplatin and 3 patients had grade 2-3 toxicity.
Poisson
M
M
Department of Neurology, La Salpêtrière, Paris, France.
Péréon
Y
Y
Chiras
J
J
Delattre
J Y
JY
D000328:Adult; D000818:Animals; D001254:Astrocytoma / Q000188:drug therapy / Q000628:therapy; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000628:therapy; D016190:Carboplatin / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy / Q000628:therapy; D005910:Glioma / Q000188:drug therapy* / Q000628:therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D009837:Oligodendroglioma / Q000188:drug therapy / Q000628:therapy; D010198:Pancytopenia / Q000139:chemically induced; D014839:Vomiting / Q000139:chemically induced
D016190:Carboplatin